Skip to main content
Clinical Trials/IRCT20220121053776N1
IRCT20220121053776N1
Recruiting
Phase 2

Evaluation of the efficacy, safety, satisfaction and tolerability of treatment with diluted botulinum toxin A in comparison with intralesional triamcinolone in patients undergone PDL laser for Hypertrophic erythematous scars: A blinded randomized controlled clinical trial

Iran University of Medical Sciences0 sites12 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
12
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients over 18 years
  • Patients with a confirmed diagnosis of hypertrophic erythematous scars of at least 3
  • The size of the mentioned lesions should be at least 10 × 10 cm or have a length of at least 10 cm
  • The patient is not pregnant or breast feeding
  • The patient has not received any treatment for lesions such as laser, topical or injectable corticosteroids in the past two months
  • The patient has no underlying diseases that lead to the healing process of the scar; Such as diabetes or weakened immune system
  • The patient's cooperation in performing medical interventions and referring to all treatment sessions

Exclusion Criteria

  • Occurrence of pregnancy during treatment or follow\-up period
  • The occurrence of allergies or any side effects to one of the therapeutic interventions that prevent further treatment
  • Diagnosis of malignancy or systemic disease during treatment or follow\-up period
  • The appearance of bacterial or viral skin diseases during treatment or follow\-up

Outcomes

Primary Outcomes

Not specified

Similar Trials